InMed and BayMedica hosted a live webinar to talk about InMed’s acquisition of BayMedica, how it positions the company as a leader in the manufacturing of rare cannabinoids, and the plans for the newly combined company.
On September 13th, InMed Pharmaceuticals announced it had signed a definitive agreement to acquire BayMedica, a leading commercial manufacturer of rare cannabinoids, based in California and Nevada. With this acquisition, InMed is positioned to become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and appropriate quality specifications for the desired market segment. In parallel to cannabinoid manufacturing, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, as well as expand commercial sales of rare cannabinoids to the consumer health and wellness sector.
